



## Altimune to Present at Upcoming Investor Conferences

May 16, 2022 at 7:30 AM EDT

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in May 2022:

- **H.C. Wainwright Global Investment Conference**

Tuesday, May 24, 2022

*7:00 am Eastern Time*

The session will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

- **B. Riley Securities Institutional Investor Conference**

Thursday, May 26, 2022

*1:00 pm Pacific Time*

The session will be an in person fireside chat.

### About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

### Altimune Investor & Media Contact:

Richard Eisenstadt

Chief Financial Officer

Phone: 240-654-1450

[reisenstadt@altimmune.com](mailto:reisenstadt@altimmune.com)



Source: Altimune, Inc